Moreover, a recent target of interest in ACC is the prostate-specific membrane antigen (PSMA), which is commonly expressed in several SGC subtypes; preliminary findings with 177Lu-PSMA radioligand therapy in ACC and SDC showed limited results with only stable disease achieved in ACC and only early progression in SDC [48]. This evidence concerns the gene FOLH1 and adrenal cortex carcinoma.